

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P0998D2

Serial No.

091648-896

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Cleland et al.

Filing Date

25 Aug 2000

Group

1641

JAN 09 2001

U.S. PATENT DOCUMENTS

TECH CENTER 1600/2900

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
CX ↓ ✓	* 1	08/508,014		Fick et al.			27.07.95
	* 2	4,093,606	06.06.78	Coval, M.			
	* 3	4,499,073	12.02.85	Tenold, R.			
	* 4	4,753,894	28.06.88	Frankel et al.			
	* 5	4,877,608	31.10.89	Lee, T. et al.			
	* 6	4,891,319	02.01.90	Roser			
	7	4,935,341	19.06.90	Bargmann et al.			
	* 8	4,940,782	10.07.90	Rup et al.			
	* 9	4,943,533	24.07.90	Mendelsohn et al.			
	* 10	4,968,603	06.11.90	Slamon et al.			
	* 11	4,975,278	04.12.90	Senter, P. et al.			
	* 12	5,032,405	16.07.91	Huang, H. et al.			
	* 13	5,036,049	30.07.91	Audhya, T. et al.			
	* 14	5,096,885	17.03.92	Pearlman et al.			
	* 15	5,149,653	22.09.92	Roser			
	* 16	5,169,774	08.12.92	Frankel et al.			
	* 17	5,183,884	02.02.93	Kraus et al.			
	* 18	5,215,743	01.06.93	Singh, M. et al.			
	* 19	5,262,296	16.11.93	Ogawa, E. et al.			
	20	5,288,477	22.02.94	Bacus, S.			
	21	5,359,046	25.10.94	Capon et al.			
	* 22	5,367,060	22.11.94	Vandlen et al.			
	* 23	5,399,670	21.03.95	Bhattacharya, P. et al.			
	24	5,401,638	28.03.95	Carney et al.			
	* 25	5,410,025	25.04.95	Moller et al.			
	* 26	5,464,751	07.11.95	Greene et al.			
	* 27	5,480,968	02.01.96	Kraus et al.			
	* 28	5,514,554	07.05.96	Bacus, S.			
	* 29	5,571,894	05.11.96	Wels, W. et al.			
	30	5,578,482	26.11.96	Lippman et al.			
	* 31	5,580,856	03.12.96	Prestrelski et al.			
	* 32	5,587,458	24.12.96	King, C. et al.			
	* 33	5,589,167	31.12.96	Cleland et al.			
	34	5,604,107	18.02.97	Carney et al.			
	* 35	5,608,038	04.03.97	Eibl et al.			
	* 36	5,641,869	24.06.97	Vandlen et al.			

Examiner

Christopher H Yan

Date Considered

12/9/01

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P0998D2

Serial No.

09,648,896

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Cleland et al.

Filing Date

25 Aug 2000

Group

1641

U.S. PATENT DOCUMENTS

TECH CENTER 1800/2300

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
CY	37	5,663,144	02.09.97	Greene et al.			
	* 38	5,677,171	14.10.97	Hudziak et al.			
	39	5,705,157	06.01.98	Greene			
	* 40	5,720,937	24.02.98	Hudziak et al.			
	* 41	5,720,954	24.02.98	Hudziak et al.			
	* 42	5,725,856	10.03.98	Hudziak et al.			
	43	5,726,023	10.03.98	Cheever et al.			
	44	5,728,687	17.03.98	Bissery			
	* 45	5,747,261	05.05.98	King et al.			
	* 46	5,763,409	09.06.98	Bayol et al.			
	* 47	5,770,195	23.06.98	Hudziak et al.			
	* 48	5,772,997	30.06.98	Hudziak et al.			
	* 49	5,776,427	07.07.98	Thorpe et al.			
	* 50	5,783,186	21.07.98	Arakawa et al.			
	51	5,801,005	01.09.98	Cheever et al.			
	* 52	5,821,337	13.10.98	Carter et al.			
	* 53	5,824,311	20.10.98	Greene et al.			
	* 54	5,834,229	10.11.98	Vandlen et al.			
	55	5,837,243	17.11.98	Deo et al.			
	56	5,837,523	17.11.98	Greene et al.			
	* 57	5,840,525	24.11.98	Vandlen et al.			
	58	5,846,538	08.12.98	Cheever et al.			
	* 59	5,849,700	15.12.98	Sorensen et al.			
	* 60	5,856,110	05.01.99	Vandlen et al.			
	* 61	5,859,206	12.01.99	Vandlen et al.			
	62	5,869,445	09.02.99	Cheever et al.			
	63	5,876,712	02.03.99	Cheever et al.			
	64	5,877,305	02.03.99	Huston et al.			
	65	5,908,835	01.06.99	Bissery			
	66	5,910,486	08.01.99	Curiel et al.			
	67	5,922,845	13.07.99	Deo et al.			
	68	5,939,531	17.08.99	Wels et al.			
	69	5,977,322	02.11.99	Marks et al.			
	* 70	5,985,553	16.11.99	King et al.			
	* 71	6,015,567	18.01.00	Hudziak et al.			
	* 72	6,028,059	22.02.00	Curiel et al.			

Examiner

Christopher Yae

Date Considered

12/4/01

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P0998D2

Serial No.

09/648,896

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Cleland et al.

Filing Date

25 Aug 2000

Group

1641

JAN 09 2001

U.S. PATENT DOCUMENTS

TECH CENTER 1600/2900

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
cy	73	6,054,297	25.04.00	Carter et al.			
	* 74	6,054,561	25.04.00	Ring			
	75	6,123,939	26.09.00	Shawver et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No
cy	* 76	AU-B-30771/89	07.09.89	AUSTRALIA			
	* 77	2,138,853	29.06.95	CANADA			
	* 78	0 531 539 A1	17.03.93	EPO			
	* 79	303,746	22.02.89	EPO			
	* 80	391,444	10.10.90	EPO			
	* 81	597,101	18.05.94	EPO			
	* 82	599,274	01.06.94	EPO			
	83	616,812	28.09.94	EPO			
	* 84	661,060	05.07.95	EPO (WITH ENGLISH ABSTRACT)			
	85	711,565	26.08.98	EPO			
	* 86	841,067	13.05.98	EPO			
	87	2,761,543B2	04.06.98	JAPAN (TRANSLATION ATTACHED)			
	88	2,895,105B2	24.05.99	JAPAN (ENGLISH ABSTRACT AND CLAIMS)			
	89	3-240498	25.10.91	JAPAN (ENGLISH ABSTRACT ATTACHED)			
	90	5-117165	14.05.93	JAPAN (ENGLISH ABSTRACT ATTACHED)			
	91	5-170667	09.07.93	JAPAN (ENGLISH ABSTRACT ATTACHED)			
	92	5-213775	24.08.93	JAPAN (ENGLISH ABSTRACT ATTACHED)			
	93	5-317084	03.12.93	JAPAN (ENGLISH ABSTRACT ATTACHED)			
	94	7-59588	07.03.95	JAPAN (ENGLISH ABSTRACT ATTACHED)			
	95	95,006,982B2	30.01.95	JAPAN (ENGLISH ABSTRACT AND CLAIMS)			
	* 96	WO 84/00890	15.03.84	PCT			
	* 97	WO 89/06692	27.07.89	PCT			
	* 98	WO 89/09402	05.10.89	PCT (WITH ENGLISH ABSTRACT)			
	* 99	WO 89/11297	30.11.89	PCT			
	*100	WO 90/11091	04.10.90	PCT			
	101	WO 92/10573	25.06.92	PCT			
	*102	WO 92/22653	23.12.92	PCT			
	*103	WO 93/05799	01.04.93	PCT			
	104	WO 93/12220	24.06.93	PCT			
	105	WO 93/21232	28.10.93	PCT			

Examiner

Christoph H Yen

Date Considered

12/7/01

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P0998D2

Serial No.

09/02/1996

RECEIVED

Applicant
Cleland et al.Filing Date
25 Aug 2000Group
1641

JAN 09 2001

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

FOREIGN PATENT DOCUMENTS

TECH CENTER 1600/2900

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No	
CY	106	WO 93/21319	28.10.93	PCT				
	*107	WO 94/00136	06.01.94	PCT				
	108	WO 94/10202	11.05.94	PCT				
	*109	WO 94/22478	13.10.94	PCT				
	110	WO 94/28127	08.12.94	PCT				
	111	WO 95/16051	15.06.95	PCT				
	112	WO 95/17507	29.06.95	PCT				
	113	WO 95/28485	26.10.95	PCT				
	114	WO 96/18409	20.06.96	PCT				
	115	WO 96/30046	03.10.96	PCT				
	*116	WO 97/20858	12.06.97	PCT				
	117	WO 97/27848	07.08.97	PCT				
	118	WO 97/38731	23.10.97	PCT				
	119	WO 97/45140	04.12.97	PCT				
	*120	WO 98/22136	28.05.98	PCT				
	121	WO 98/45479	15.10.98	PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

cx	*122	Aasland et al., "Expression of oncogenes in thyroid tumours: Coexpression of c-erbB2/neu and c-erbB" <u>British Journal of Cancer</u> 57(4):358-363 (Apr 1988)
	*123	Adams and Weiner, "Intracellular single-chain Fv antibodies--a knockout punch for neoplastic cells?" <u>Gynecologic Oncology</u> 59(1):6-7 (Oct 1995)
	*124	Arakawa et al., "Protein-Solvent Interactions in Pharmaceutical Formulations" <u>Pharmaceutical Research</u> 8(3):285-291 (1991)
	*125	Arboleda et al., "Effects of the 4D5 antibody on HER2/neu heterodimerization with other class I receptors in human breast cancer cells" <u>Proceedings of the American Association for Cancer Research</u> (Abstract #353) 37:51 (Mar 1996)
	*126	Arteaga et al., "p185 ^{c-erbB-2} Signaling Enhances Cisplatin-induced Cytotoxicity in Human Breast Carcinoma Cells: Association Between an Oncogenic Receptor Tyrosine Kinase and Drug-induced DNA Repair" <u>Cancer Research</u> 54(14):3758-3765 (Jul 15, 1994)
	*127	Bacus et al., "Differentiation of Cultured Human Breast Cancer Cells (AU-565 and MCF-7) Associated With Loss of Cell Surface HER-2/neu Antigen" <u>Molecular Carcinogenesis</u> 3(6):350-362 (1990)
	*128	Bacus et al., "Tumor-inhibitory Monoclonal Antibodies to the HER-2/Neu Receptor Induce Differentiation of Human Breast Cancer Cells" <u>Cancer Research</u> 52(9):2580-2589 (May 1, 1992)
	*129	Bam et al., "Stability of Protein Formulations: Investigation of Surfactant Effects by a Novel EPR Spectroscopic Technique" <u>Pharm. Res.</u> 12:2-11 (1995)
	130	Baselga et al., "Anti HER2 Humanized Monoclonal Antibody (MAb) Alone and in Combination with Chemotherapy Against Human Breast Carcinoma Xenografts" <u>Proceedings of ASCO-13th Annual Meeting</u> (Abstract #53), Dallas, TX 13:63 (Mar 1994)
	131	Baselga et al., "Monoclonal antibodies directed against growth factor receptors enhance the efficacy of chemotherapeutic agents" <u>Annals of Oncology</u> (abstract #010) 5(Suppl. 5) (1994)

Examiner

Christopher Yaen

Date Considered

12/9/01

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P0998D2Serial No.
09/600,896

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant
Cleland et al.Filing Date
25 Aug 2000Group
1641

JAN 09 2001

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

TECH CENTER 1600/2900

*132	Baselga et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185HER2 Monoclonal Antibody in Patients With HER2/neu-Overexpressing Metastatic Breast Cancer" <u>J. Clin. Oncol.</u> 14(3):737-744 (Mar 1996)
*133	Baselga et al., "Receptor Blockade With Monoclonal Antibodies As Anti-Cancer Therapy" <u>Pharmac. Ther.</u> 64:127-154 (1994)
*134	Beauvais et al., "Both Glassy State and Native Structure are Required for Storage Stability of Lyophilized Interleukin-1 Receptor Antagonist" <u>Pharm. Res.</u> (Abstract #2007) 12(9):S-80 (1995)
*135	Borst et al., "Oncogene Alterations in Endometrial Carcinoma" <u>Gynecologic Oncology</u> 38(3):364-366 (Sep 1990)
*136	Boulet et al., "Inhibitory Effects of an Anti-IgE Antibody E25 on Allergen-induced Early Asthmatic Response" <u>Am J Respir Crit Care Med</u> 155:1835-1840 (1997)
*137	Carraway et al., "A Neu Acquaintance for ErbB3 and ErbB4: A Role for Receptor Heterodimerization in Growth Signaling" <u>Cell</u> 78:5-8 (Jul 15, 1994)
*138	Carter et al., "Humanization of an anti-p185HER2 antibody for human cancer therapy" <u>Proc. Natl. Acad. Sci.</u> 89:4285-4289 (1992)
*139	Chang and Fischer, "Development of an Efficient Single-Step Freeze-Drying Cycle for Protein Formulations" <u>Pharm. Res.</u> 12(6):831-837 (1995)
*140	Chang et al., "Development of a Stable Freeze-dried Formulation of Recombinant Human Interleukin-1 Receptor Antagonist" <u>Pharmaceutical Research</u> 13(2):243-248 (1996)
*141	Cleland and Jones, "Development of Stable Protein Formulations for Microencapsulation in Biodegradable Polymers" <u>Proceed. Intern. Symp. Control. Rel. Bioact. Mater.</u> 22:514-515 (1995)
*142	Cleland et al., "The Development of Stable Protein Formulations: A Close Look at Protein Aggregation, Deamidation, and Oxidation" <u>Critical Reviews in Therapeutic Drug Carrier Systems</u> 10(4):307-377 (1993)
*143	Cohen et al., "Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract" <u>Oncogene</u> 4(1):81-88 (Jan 1989)
*144	D'souza et al., "Overexpression of ERBB2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene" <u>Proc. Natl. Acad. Sci. USA</u> 91(15):7202-7206 (Jul 19, 1994)
*145	Darzynkiewicz et al., "Features of apoptotic cells measured by flow cytometry" <u>Cytometry</u> 13(8):795-808 (1992)
*146	De Santes et al., "Radiolabeled Antibody Targeting of the HER-2/neu Oncoprotein" <u>Cancer Research</u> 52:1916-1923 (1992)
*147	Deshane et al., "Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis" <u>Cancer Gene Therapy</u> 3(2):89-98 (Mar-Apr 1996)
*148	Deshane et al., "Intracellular antibody knockout of the ERBB2 oncoprotein achieves targeted eradication of tumor targets by induction of apoptosis" <u>Journal of Investigative Medicine</u> 43(Suppl. 2):328A (1995)
*149	Deshane et al., "Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody" <u>Gynecologic Oncology</u> 59(1):8-14 (Oct 1995)
*150	Deshane et al., "Targeted tumor killing via an intracellular antibody against erbB-2" <u>Journal of Clinical Investigation</u> 96(6):2980-2989 (Dec 1995)
*151	Deshane et al., "Transductional Efficacy and Safety of an Intraperitoneally Delivered Adenovirus Encoding an Anti-erbB-2 Intracellular Single-Chain Antibody for Ovarian Cancer Gene Therapy" <u>Gynecologic Oncology</u> 64(3):378-385 (Mar 1997)

Examiner

Christopher H. Yuen

Date Considered

12/8/01

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P0998D2Serial No.
097816, 99

RECEIVED

Applicant
Cleland et al.Filing Date
25 Aug 2000Group
1641JAN 09 2001
TECH CENTER 1600/2900

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

CY	*152	Digiesi et al., "Production and characterization of murine mAbs to the extracellular domain of human neu oncogene product GP185HER2" <u>Hybridoma</u> 11(4):519-527 (Aug 1992)
	*153	Draber et al., "Stability of Monoclonal IgM Antibodies Freeze-Dried in the Presence of Trehalose" <u>Journal of Immunological Methods</u> 181(1):37-43 (1995)
	*154	Drebin et al., "Down-Modulation of an Oncogene Protein Product and Reversion of the Transformed Phenotype by Monoclonal Antibodies" <u>Cell</u> 41(3):695-706 (Jul 1985)
	*155	Drebin et al., "Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen" <u>Proc. Natl. Acad. Sci.</u> 83:9129-9133 (1986)
	*156	Drebin et al., "Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo" <u>Oncogene</u> 2:273-277 (1988)
	*157	Drebin et al., "Monoclonal Antibodies Specific for the neu Oncogene Product Directly Mediate Anti-tumor Effects In Vivo" <u>Oncogene</u> 2(4):387-394 (1988)
	*158	Fahy et al., "The Effect of an Anti-IgE Monoclonal Antibody on the Early- and Late-Phase Responses to Allergen Inhalation in Asthmatic Subjects" <u>Am J Respir Crit Care Med</u> 155:1828-1834 (1997)
	*159	Fendly et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product" <u>Cancer Research</u> 50:1550-1558 (Mar 1, 1990)
	*160	Fraker and Speck Jr., "Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril" <u>Biochemical & Biophysical Research Communications</u> 80(4):849-857 (Feb 28, 1978)
	*161	Fukushige et al., "Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line" <u>Molecular & Cellular Biology</u> 6(3):955-958 (Mar 1986)
	*162	(Genentech, Inc. Proposal Request and Material Transfer Agreement with Richard H. Scheuermann (1993), 3 pages, and letters in relation to it dated June 23, 1993 and October 20, 1993)
	*163	Grim et al., "The level of erbB2 expression predicts sensitivity to the cytotoxic effects of an intracellular anti-erbB2 sFv" <u>Journal of Molecular Medicine</u> 76(6):451-458 (May 1998)
	*164	Groenen et al., "Structure-Function Relationships for the EGF/TGF- α Family of Mitogens" <u>Growth Factors</u> 11:235-257 (1994)
	*165	Guerin et al., "Overexpression of Either c-myc or c-erbB-2/neu Proto-Oncogenes in Human Breast Carcinomas: Correlation with Poor Prognosis" <u>Oncogene Res</u> 3:21-31 (1988)
	166	Guy et al., "Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease" <u>Proc. Natl. Acad. Sci. USA</u> 89(22):10578-10582 (Nov 15, 1992)
	*167	Hancock et al., "A Monoclonal Antibody against the c-erbB-2 Protein Enhances the Cytotoxicity of cis-Diamminedichloroplatinum against Human Breast and Ovarian Tumor Cell Lines" <u>Cancer Research</u> 51:4575-4580 (Sep 1, 1991)
	*168	Harwerth et al., "Monoclonal Antibodies against the Extracellular Domain of the erbB-2 Receptor Function as Partial Ligand Agonists" <u>Journal of Biological Chemistry</u> 267(21):15160-15167 (Jul 25, 1992)
	169	"Herceptin (Trastuzumab)" <u>Product Information</u> (2000)
	*170	Hudziak et al., "Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells" <u>Proc. Natl. Acad. Sci.</u> 84(20):7159-7163 (Oct 1987)
	*171	Hudziak et al., "p185HER2 Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor" <u>Molecular & Cellular Biology</u> 9(3):1165-1172 (Mar 1989)

Examiner

Christopher Yaen

Date Considered

12/8/00

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P0998D2Serial No.
09/648,896

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant
Cleland et al.Filing Date
25 Aug 2000Group
1641

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

172	Hynes and Stern, "The biology of erbB-2/neu/HER-2 and its role in cancer" <u>Biochimica et Biophysica Acta</u> 1198(2-3):165-184 (Dec 30, 1994)
*173	Ilgen et al., "Characterization of anti-HER/2 antibodies which inhibit the growth of breast tumor cells in vitro" <u>Proceedings of the American Association for Cancer Research</u> (abstract #3209) 37:470 (Mar 1996)
*174	Ilgen et al., "Characterization of anti-HER/2 monoclonal antibodies which inhibit the growth of breast cancer cell lines in vitro" <u>Proceedings of the American Association for Cancer Research</u> (Abstract #564) 38:84 (Mar 1997)
*175	"Immune Globulin Intravenous (Human) Sandoglobulin" <u>Product Information, Physicians' Desk Reference</u> pps. 2075-2077 (1994)
*176	"IVEEGAM", "Product Information, IMMUNO U.S., Inc." pps. 2 pages (1992)
*177	Izutsu et al., "The effects of additives on the stability of freeze-dried β -galactosidase stored at elevated temperature" <u>Intl. J. Pharmaceutics</u> 71:137-146 (1991)
*178	Kasprzyk et al., "Therapy of an Animal Model of Human Gastric Cancer Using a Combination of Anti-erbB-2 Monoclonal Antibodies" <u>Cancer Research</u> 52(10):2771-2776 (May 15, 1992)
*179	Kern et al., "p185neu Expression in Human Lung Adenocarcinomas Predicts Shortened Survival" <u>Cancer Research</u> 50(16):5184-5191 (Aug 15, 1990)
*180	King et al., "Amplification of a Novel v-erbB-Related Gene in a Human Mammary Carcinoma" <u>Science</u> 229:974-976 (Sept 1985)
*181	Kita et al., "ErbB receptor activation, cell morphology changes, and apoptosis induced by anti-Her2 monoclonal antibodies" <u>Biochemical & Biophysical Research Communications</u> 226(1):59-69 (Sep 4, 1996)
*182	Klapper et al., "A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors" <u>Oncogene</u> 14:2099-2109 (1997)
*183	Kotts et al., "Differential Growth Inhibition of Human Carcinoma Cells Exposed to Monoclonal Antibodies Directed against the Extracellular Domain of the HER2/ERBB2 Protooncogene" <u>In Vitro</u> (Abstract #176) 26(3):59A (1990)
*184	Kotts et al., "Differential Growth Inhibition of Human Carcinoma Cells Exposed to Monoclonal Antibodies Directed Against the Extracellular Domain of the HER2/ERBB2 Protooncogene" (poster presented at the Annual Meeting of the Tissue Culture Association held in Houston, Texas on June 1990) pps. 1-13
*185	Kotts et al., "Growth Inhibition of Human Breast Carcinoma Cells Exposed to Combinations of Interferon-Gamma and Monoclonal Antibodies Directed Against the Extracellular Domain of the Her2/erbB2 Oncogene Protein" <u>FASEB Journal</u> (abstract #1470) 4(7):A1946 (1990)
*186	Kumar et al., "Regulation of Phosphorylation of the c-erbB-2/HER2 Gene Product by a Monoclonal Antibody and Serum Growth Factor(s) in Human Mammary Carcinoma Cells" <u>Molecular & Cellular Biology</u> 11(2):979-986 (Feb 1991)
*187	Lee et al., "Transforming Growth Factor α : Expression, Regulation, and Biological Activities" <u>Pharmacological Reviews</u> 47(1):51-85 (Mar 1995)
*188	Lemke, G., "Neuregulins in Development" <u>Molecular and Cellular Neuroscience</u> 7:247-262 (1996)
*189	Levi et al., "The Influence of Heregulins on Human Schwann Cell Proliferation" <u>J. Neuroscience</u> 15(2):1329-1340 (Feb 1995)
*190	Lewis et al., "Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies" <u>Cancer Immunol. Immunother.</u> 37:255-263 (1993)
*191	Lewis et al., "Growth Regulation of Human Breast and Ovarian Tumor Cells by Heregulin: Evidence for the Requirement of ErbB2 as a Critical Component in Mediating Heregulin Responsiveness" <u>Cancer Research</u> 56:1457-1465 (Mar 15, 1996)


Examiner

Christopher Yuen

Date Considered

12/2/01

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PT0-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P0998D2

Serial No.

09/648,896

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Cleland et al.

Filing Date

25 Aug 2000

Group

1641

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

ey	*192	Maier et al., "Requirements for the Internalization of a Murine Monoclonal Antibody Directed against the HER-2/neu Gene Product c-erbB-2" <u>Cancer Research</u> 51(19):5361-5369 (Oct 1, 1991)
	*193	Manning et al., "Stability of Protein Pharmaceuticals" <u>Pharm. Res.</u> 6(11):903-918 (1989)
	*194	Marth et al., "Effects of Interferons on the expression of the proto-oncogene HER-2 in human ovarian carcinoma cells" <u>International Journal of Cancer</u> 50(1):64-68 (Jan 2, 1992)
	*195	Masui et al., "Growth Inhibition of Human Tumor Cells in Athymic Mice by Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies" <u>Cancer Research</u> 44(3):1002-1007 (Mar 1984)
	*196	Masuko et al., "A murine Monoclonal Antibody That Recognizes an Extracellular Domain of the Human c-erbB-2 Protooncogene Product" <u>Jpn J. Cancer Res.</u> 80:10-14 (January 1989)
	*197	McCann et al., "c-erbB-2 Oncoprotein Expression in Primary Human Tumors" <u>Cancer</u> 65(1):88-92 (Jan 1, 1990)
	*198	McKenzie et al., "Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185" <u>Oncogene</u> 4:543-548 (1989)
	199	Mendelsohn et al., "Receptor blockade and chemotherapy: a new approach to combination cancer therapy" <u>Annals of Oncology</u> (abstract #040) 7(Suppl. 1):22 (1996)
	*200	Moore et al., "Apoptosis in CHO Cell Batch Cultures: Examination by Flow Cytometry" <u>Cytotechnology</u> 17:1-11 (1995)
	*201	Morrissey et al., "Axon-induced mitogenesis of human Schwann cells involves heregulin and p185 ^{erbB2} " <u>Proc. Natl. Acad. Sci. USA</u> 92:1431-1435 (Feb 1995)
	*202	Myers et al., "Biological Effects of Monoclonal Antireceptor Antibodies Reactive with neu Oncogene Product, p185 ^{neu} " <u>Methods in Enzymology</u> 198:277-290 (1991)
	*203	Nielsen, et al., "Stability of Freeze Dried Horseradish Peroxidase Conjugated Monoclonal Antibodies Used in Diagnostic Serology" <u>Journal of Immunoassay</u> 16(2):183-197 (1995)
	204	Norton, L., "Evolving concepts in the systemic drug therapy of breast cancer" <u>Seminars in Oncology</u> 24(4 Suppl 10):S10-3-S10-10 (Aug 1997)
	*205	Park et al., "Amplification, Overexpression, and Rearrangement of the erbB-2 Protooncogene in Primary Human Stomach Carcinomas" <u>Cancer Research</u> 49(23):6605-6609 (Dec 1, 1989)
	*206	Pearlman et al., "Analysis of Protein Drugs" <u>Peptide and Protein Drug Delivery</u> , Vincent H. L. Lee, Marcel Dekker, Inc., Chapter 6, pps. 247-301 (1991)
	*207	Pickar et al., "Control of lymphocyte recirculation in man. I. Differential regulation of the peripheral lymph node homing receptor L-selectin on T cells during the virgin to memory cell transition" <u>Journal of Immunology</u> 150(3):1105-1121 (Feb 1, 1993)
	*208	Pietras et al., "Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells" <u>Oncogene</u> 9:1829-1838 (1994)
	*209	Pikal et al., "The Effects of Formulation Variables on the Stability of Freeze-Dried Human Growth Hormone" <u>Pharm. Res.</u> 8:427-436 (1991)
	*210	Pikal, M., "Freeze-Drying of Proteins, Part 2: Formulation Selection" <u>Biopharm.</u> 3(9):26-30 (1990)
	*211	Plowman et al., "Heregulin induces tyrosine phosphorylation of HER4/p180 ^{erbB4} " <u>Nature</u> (Letters to Nature) 366:473-475 (Dec 2, 1993)

Examiner

Christopher H Yan

Date Considered

12/9/00

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PT0-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P0998D2

Serial No.

09/648,896

Applicant

Cleland et al.

Filing Date

25 Aug 2000

Group

1641

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

e-y	*212	Plowman et al., "Ligand-specific activation of HER4/p180 ^{erbB4} , a fourth member of the epidermal growth factor receptor family" <u>Proc. Natl. Acad. Sci. USA</u> 90:1746-1750 (Mar 1993)
f	*213	Presta et al., "Humanization of an Antibody Directed Against IgE" <u>J. Immunol.</u> 151(5):2623-2632 (September 1, 1993)
	*214	Price et al., "Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice" <u>Cancer Research</u> 50(3):717-721 (Feb 1, 1990)
	215	Ravdin and Chamness, "The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review" <u>Gene</u> 159(1):19-27 (Jun 14, 1995)
	*216	Ring et al., "Distribution and Physical Properties of BCA200, a Mr 200,000 Glycoprotein Selectively Associated with Human Breast Cancer" <u>Cancer Research</u> 49:3070-3080 (Jun 1, 1989)
	*217	Ring et al., "Identity of BCA200 and c-erbB-2 Indicated by Reactivity of Monoclonal Antibodies with Recombinant c-erbB-2" <u>Molecular Immunology</u> 28(8):915-917 (1991)
	*218	Rodeck et al., "Interactions between growth factor receptors and corresponding monoclonal antibodies in human tumors" <u>J. Cellular Biochem.</u> 35(4):315-320 (1987)
	*219	"Sandoglobulin" <u>Physicians' Desk Reference</u> pps. 1965-1966 (1991)
	*220	Sarup et al., "Characterization of an Anti-P185 ^{HER2} Monoclonal Antibody that Stimulates Receptor Function and Inhibits Tumor Cell Growth" <u>Growth Regulation</u> 1:72-82 (1991)
	*221	Scheuermann, R., "Anti-HER2 Effects" (slide which may have been (but was probably not) presented at a seminar by Scheuermann at Syntex on August 3, 1994)
	*222	Schlom, J., "Monoclonal Antibodies: They're More and Less Than You Think" <u>Molecular Foundations of Oncology</u> , Broder, S. ed., Baltimore, MD:Williams & Wilkins, Chapter 6, pps. 95-134 (1991)
	*223	Scott et al., "p185 ^{HER2} Signal Transduction in Breast Cancer Cells" <u>Journal of Biological Chemistry</u> 266(22):14300-14305 (Aug 5, 1991)
	*224	Shawver et al., "Ligand-like Effects Induced by Anti-c-erbB-2 Antibodies Do Not Correlate with and Are Not Required for Growth Inhibition of Human Carcinoma Cells" <u>Cancer Research</u> 54(5):1367-1373 (Mar 1, 1994)
	*225	Shepard et al., "Monoclonal Antibody Therapy of Human Cancer: Taking the HER2 Protooncogene to the Clinic" <u>J. Clin. Immunol.</u> 11(3):117-127 (1991)
	*226	Slamon et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene" <u>Science</u> 235:177-182 (Jan 9, 1987)
	*227	Slamon et al., "Studies of the HER-2/neu Proto-oncogene in Human Breast and Ovarian Cancer" <u>Science</u> 244:707-712 (May 12, 1989)
	*228	Sliwkowski et al., "A humanized monoclonal antibody for the treatment of HER2 overexpressing breast cancer" <u>Proceedings of the American Association for Cancer Research</u> 37:625-626 (Mar 1996)
	*229	Sliwkowski et al., "Coexpression of erbB2 and erbB3 Proteins Reconstitutes a High Affinity Receptor for Heregulin" <u>Journal of Biological Chemistry</u> 269(20):14661-14665 (May 20, 1994)
	*230	Stancovski et al., "Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth" <u>Proc. Natl. Acad. Sci. USA</u> 88(19):8691-8695 (Oct 1, 1991)
	*231	Tagliabue et al., "Selection of monoclonal antibodies which induce internalization and phosphorylation of p185 ^{HER2} and growth inhibition of cells with HER2/NEU gene amplification" <u>International Journal of Cancer</u> 47(6):933-937 (Apr 1, 1991)

Examiner

Christopher Yuen

Date Considered

12/9/01

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PT0-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P0998D2

Serial No.

09/648,896

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Cleland et al.

Filing Date

25 Aug 2000

Group

1641

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

cy	*232	Trauth et al., "Monoclonal antibody-mediated tumor regression by induction of apoptosis" <u>Science</u> 245:301-305 (1989)
	*233	Vitetta et al., "Monoclonal Antibodies as Agonists: An Expanded Role for Their Use in Cancer Therapy" <u>Cancer Research</u> 54(20):5301-5309 (Oct 15, 1994)
	*234	Vollmers et al., "Apoptosis of stomach carcinoma cells induced by a human monoclonal antibody" <u>Cancer</u> 76(4):550-558 (Aug 15, 1995)
	*235	Wang et al., "Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers" <u>J. Parenteral Sci. Tech.</u> (Technical Report No. 10) 42(2S):S4-S26 (1988)
	*236	Weiner et al., "Expression of the neu Gene-encoded Protein (P185 ^{neu}) in Human Non-Small Cell Carcinomas of the Lung" <u>Cancer Research</u> 50(2):421-425 (Jan 15, 1990)
	*237	Weller et al., "Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines" <u>Journal of Clinical Investigation</u> 94(3):954-964 (Sep 1994)
	*238	Williams et al., "Expression of c-erbB-2 in Human Pancreatic Adenocarcinomas" <u>Pathobiology</u> 59(1):46-52 (1991)
	*239	Wright et al., "An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2" <u>Gene Therapy</u> 4(4):317-322 (Apr 1997)
	*240	Wu et al., "Apoptosis Induced By an Anti-Epidermal Growth Factor Receptor Monoclonal Antibody in a Human Colorectal Carcinoma Cell Line and Its Delay By Insulin" <u>Journal of Clinical Investigation</u> 95(4):1897-1905 (Apr 1995)
	*241	Xu et al., "Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185" <u>International Journal of Cancer</u> 53(3):401-408 (Feb 1, 1993)
	*242	Yamamoto et al., "Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor" <u>Nature</u> 319:230-234 (1986)
	*243	Yokota et al., "Amplification of c-erbB-2 Oncogene in Human Adenocarcinomas in Vivo" <u>Lancet</u> 1(8484):765-767 (Apr 5, 1986)
	*244	Yonemura et al., "Evaluation of Immunoreactivity for erbB-2 Protein as a Marker of Poor Short Term Prognosis in Gastric Cancer" <u>Cancer Research</u> 51(3):1034-1038 (Feb 1, 1991)
	*245	Zhang et al., "Relative malignant potential of human breast carcinoma cell lines established from pleural effusions and a brain metastasis" <u>Invasion Metastasis</u> 11(4):204-215 (1991)
	*246	Zhang et al., "Shared antigenic epitopes and pathobiological functions of anti-p185 ^{her2/neu} monoclonal antibodies" <u>Experimental and Molecular Pathology</u> 67:15-25 (1999)
Y	*247	Zhou et al., "Amplification and Expression of the c-erb B-2/neu Proto-Oncogene in Human Bladder Cancer" <u>Molecular Carcinogenesis</u> 3(5):254-257 (1990)

Examiner

Christopher Yae

Date Considered

12/8/01

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.